AI Article Synopsis
- The study analyzed sulfamethazine acetylation in 49 colorectal cancer patients and two control groups of older and younger subjects.
- Metabolic clearance and specific plasma and urinary ratios were used to categorize individuals as slow or fast acetylators, with consistent results across all measures.
- The findings indicated that a higher proportion of fast acetylators was present in the cancer group compared to the controls, suggesting a potential link between acetylation phenotype and colorectal cancer.
Article Abstract
Sulfamethazine acetylation phenotype was determined in 49 patients with cancer of the colon or rectum, 41 old, and 45 young control subjects. Metabolic clearance of sulfamethazine, plasma ratio of N-acetylsulfamethazine:N-acetylsulfamethazine plus sulfamethazine and urinary ratio of N-acetylsulfamethazine:N-acetylsulfamethazine plus sulfamethazine were used to classify subjects into slow and fast acetylation phenotypes. All three measures gave similar results. The proportions of slow and fast acetylators were similar in both control groups and there were significantly more fast acetylators in the cancer group than in the control groups (chi 2 = 5.0-8.5; P less than 0.05). The data suggest that there may be an association between acetylation phenotype and colorectal carcinoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!